SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clin. Pharm. 1991; 10: 335358.
  • 2
    Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997; 6: 8793.
  • 3
    Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin. Pharmacokinet. 1992; 22: 1121.
  • 4
    Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 11111117.
  • 5
    Pellock JM, Smith MC, Cloyd JC, Uthman B, Wilder BJ. Extended-release formulations: Simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav. 2004; 5: 301307.
  • 6
    Perucca E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695714.
  • 7
    Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr. Scand. Suppl. 2005; 426: 1320.
  • 8
    Nasrallah HA, Ketter TA, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: A review of the literature. J. Affect. Disord. 2006; 95: 6978.
  • 9
    Gugler G, Von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin. Pharmacokinet. 1980; 5: 6783.
  • 10
    Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid 1988. Clin. Pharmacokinet. 1988; 15: 367389.
  • 11
    Eadie MJ. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance. Clin. Pharmacokinet. 1991; 21: 2741.
  • 12
    Doughty J, Baker GA, Jacoby A, Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 2003; 4: 710716.
  • 13
    Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: A new formulation for valproate. Acta Neurol. Scand. Suppl. 2005; 182: 2632.
  • 14
    Fujisaki Y, Tsukune T, Funyu M, Okumura M, Ukigaya T, Sugibayashi K. Development of sustained-release tablets containing sodium valproate: In vitro and in vivo correlation. Drug Dev. Ind. Pharm. 2006; 32: 207217.
  • 15
    Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised, DHEW Publications No. 76–338. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, 1976.
  • 16
    Sommerville KW. Bioequivalence in development of antiepileptic drugs. Epilepsy Res. 2006; 68: 8285.
  • 17
    Yasui-Furukori N, Kondo T, Kaneko S. Comparison of pharmacokinetics and bioequivalence of valproic acid between two sustained-formulations, Depakene R. 200 mg tablet and Selenica R. 200 mg tablet. Pharma Med. 2005; 23: 7175 (in Japanese).